PYX-201, the Company’s lead clinical drug candidate, is a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets ...

The investment firm said that based on the data, it was lowering it probability for success for PYX-201 to 10% from 35%. It added that as it doesn’t see another stock-moving catalyst event until ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in ...

Pyxis Oncology plans to further investigate PYX-201 in additional HNSCC cohorts, particularly in combination with the drug Keytruda, following a collaboration agreement with Merck. Despite an ...